The safety outcome was the incidence of adverse events (risk ratio: 1.00; 95% CI [0.99, 1.00]; P = .38; I2 = 0%) and the number of patients suffering from hyperkalemia (risk ratio: 2.19; 95% CI [2.04, 2.34]; P < .00001; I2 = 0%).<h4>Conclusion</h4>Results of meta-analysis showed that Finerenone could significantly reduce urine albumin creatine ratio levels. The gene discussed is ALB; the disease is Hyperkalemia.